TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.
Using Aspirin to Improve Immunological Features of Ovarian Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
This trial is no longer recruiting — here are similar active trials
Matched by cancer type/biomarker, currently recruiting.
The goal of this clinical trial is to learn if the OATD-02 administration (orally) in monotherapy is safe and has the pharmacodynamic potential to restore and enhance tumour responses to immunotherapy through increased arginine levels or intrinsic anti-tumour activity in participants with advanced metastatic colorectal cancer, ovarian cancer, renal cancer or pancreatic cancer.
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage Dose Escalation Phase followed by a Dose Expansion Phase.
About the trial
The purpose of the study is to evaluate the effectiveness of aspirin with neoadjuvant chemotherapy for decreasing markers of immune suppression in the tumor at interval debulking surgery, in women with diagnosed ovarian, fallopian tube, or peritoneal carcinoma
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzony lub podejrzewany nowotwór złośliwy jajnika, jajowodu lub otrzewnej
- •Pacjent nigdy wcześniej nie leczył się z powodu tego nowotworu
- •Zaplanowana chemioterapia poprzedzająca operację (3-5 cykli) przed chirurgią zmniejszającą guz
- •Obecne mierzalne zmiany widoczne w badaniu tomografii komputerowej
- •Dobry ogólny stan zdrowia (skala 0-2)
- •Możliwość pobrania próbki tkanki do badań
- •Możliwość przyjmowania leków w postaci tabletek
✗ Disqualifies
- •Jeśli aspiryna lub podobne leki stanowią dla Ciebie zagrożenie
- •Liczba płytek krwi poniżej 100 000 na mikroliter
- •Niemożliwość uczestniczenia w wizytach kontrolnych i badaniach wymaganych przez badanie
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 15, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (4)
Moffitt Cancer Center
Tampa, United States
Oregon Health and Science University
Portland, United States
University of Virginia Comprehensive Cancer Center
Charlottesville, United States
Inova Schar Cancer Institute
Fairfax, United States
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.